 VANCOUVER, British Columbia and SHANGHAI, Sept. 22, 2021 PRNewswire -- AbCellera Nasdaq: ABCL and Everest Medicines Limited HKEX 1952.HK, Everest announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest. 